Chromosome imbalance at the 3p14 region in human breast tumours: High frequency in patients with inherited predisposition due to BRCA2

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 142-147

  Bergthorsson, J T ^a,b   Johannsdottir, J ^a   Jonasdottir, A ^a   Eiriksdottir, G ^a   Egilsson, V ^a   Ingvarsson, S ^a   Barkardottir, R B ^a   Arason, A ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Allelic imbalance; BRCA2 carriers; Breast cancer; Chromosome 3p14

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CHROMOSOME 3P; CHROMOSOME ABERRATION; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE LOSS; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL;

BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; TRANSCRIPTION FACTORS;

EID: 0031937855     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00339-0     Document Type: Article

References (40)

1. 1. Sato T, Tanigami A, Yamakawa K, et al. Allelotype of breast cancer: Cumulative allele losses promote tumour progression in breast cancer. Cancer Res 1990, 50, 7184-7189.
2. 2. Hibi K, Takahashi T, Yamakawa K, et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992, 7, 445-449.
3. 3. Wang L, Li W, Wang X, et al. Genetic alterations on chromosomes 3 and 9 of esophageal cancer tissues from China. Oncogene 1996, 12, 699-703.
4. 4. Kovacs G, Erlandsson R, Boldog F, et al. Consistent 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 1988, 85, 1591-1595.
5. 5. Chen LC, Matsumura K, Deng G, et al. Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res 1994, 54, 3021-3024.
6. 6. Dietrich CU, Pandis N, Teixeira MR, et al. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer 1995, 60, 49-53.
7. 7. Pandis N, Jin Y, Limon J, et al. Interstitial deletion of the short arm of chromosome 3 as a primary chromosome abnormality in carcinomas of the breast. Genes Chromosom Cancer 1993, 6, 151-155.
8. 8. Tedeschi B, Vernole P, Sanna ML, Nicoletti B. Population cytogenetics of aphidicholin-induced fragile sites. Hum Genet 1992, 89, 543-547.
9. 9. Paradee W, Mullins C, He Z, et al. Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. Genomics 1995, 27, 358-361.
10. 10. Cohen AJ, Li FP, Berg S, et al. Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979, 301, 592-595.
11. 11. Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3 triphosphate hydrolase. Biochemistry 1996, 35, 11529-11535.
12. 12. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84, 587-597.
13. 13. Kastury K, Baffa R, Druck T, et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996, 56, 978-983.
14. 14. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996, 56, 3173-3179.
15. 15. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996, 85, 17-26.
16. 16. Sozzi G, Alder H, Tornielli S, et al. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res 1996, 56, 2472-2474.
17. 17. Laforgia S, Morse B, Levy J, et al. Receptor protein-tyrosine phosphatase γ is a candidate tumour suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 1991, 88, 5036-5040.
18. 18. Panagopoulos I, Pandis N, Thelin S, et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 1996, 56, 4871-4875.
19. 19. Eiriksdottir G, Bergthorsson JT, Sigurdsson H, et al. Mapping of chromosome 3 alterations in human breast cancer using microsatellite PCR markers: correlation with clinical variables. Int J Oncol 1995, 6, 369-375.
20. 20. Bergthorsson JT, Eiriksdottir G, Barkardottir RB, Egilsson V, Arason A, Ingvarsson S. Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Hum Genet 1995, 96, 437-443.
21. 21. Gudmundsson J, Johannesdottir G, Arason A, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996, 58, 749-756.
22. 22. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13-q linked kindreds. Nature Genet 1996, 12, 333-337.
23. 23. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single mutation in male and female breast cancer from Iceland with varied cancer phenotypes. Nature Genet 1996, 13, 117-119.
24. 24. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996, 56, 3663-3665.
25. 25. Bergthorsson JT, Jonasdottir A, Johannesdottir G, et al. Identification of a novel splice site mutation of the BRCA1 gene in two breast cancer families: Screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat, 1977, 79, Online http://journals.wiley.com/1059-7794/mutbrl.html.
26. 26. Teare MD, Rohde K, Koref SMF. The use of loss of constitutional heterozygosity data to ascertain the location of predisposing genes in cancer families. J Med Genet 1994, 31, 448-452.
27. 27. Smith SA, Easton DF, Evans DGR, Ponder BAJ. Allele loss in the region 17q12-21 in familial breast and ovarian cancer involve the wild type chromosome. Nature Genet 1992, 2, 128-131.
28. 28. Barkardottir RB, Arason A, Egilsson V, Gudmundsson J, Jonasdottir A, Johannesdottir G. Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer. Acta Oncol 1995, 34, 657-662.
29. 29. Kallioniemi A, Kallioniemi O-P, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genome hybridisation. Proc Natl Acad Sci USA 1994, 91, 2156-2160.
30. 30. Ardisia C, Venti G, Colossa MA, et al. Expression of aphidicholin-induced fragile sites in lymphocytes of patients with breast cancer. Cancer Genet Cytogenet 1993, 67, 113-116.
31. 31. Murata M, Otsuka M, Hayakawa Y, et al. Expressivity of a common fragile site, fra(3)(p14.2) in patients with cancer and other diseases. Jpn J Hum Genet 1992, 37, 205-213.
32. 32. Kinoshita T, Ueda M, Enomoto K, et al. Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer. Cancer 1995, 76, 2504-2509.
33. 33. Boldog F, Gemmill RM, West J, et al. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 1997, 6, 193-203.
34. 34. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266, 120-122.
35. 35. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet 1996, 13, 245-247.
36. 36. Teng DH, Bogden R, Mitchell J, et al. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genet 1996, 13, 241-244.
37. 37. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumour progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57, 1222-1227.
38. 38. Simonic I, Gericke GS. The enigma of common fragile sites. Hum Genet 1996, 97, 524-531.
39. 39. Scully R, Chen J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88, 265-275.
40. 40. Sharan SK, Morimatsu M, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997, 386, 804-810.